Bayer contemplating outsourcing more R&D as part of restructuring: Reuters

Bayer is contemplating outsourcing more of its R&D as part of an overall restructuring plan, Reuters says. (Bayer)

Bayer is contemplating outsourcing more of its R&D as part of an overall restructuring plan, Reuters reported, citing the German pharma giant’s work council.

In a statement by the work council cited by the news agency, it said Werner Baumann, Bayer’s chief executive, told employees at the group’s Leverkusen headquarters that restructuring efforts were in process, including outsourcing.

“Werner Baumann spoke about the prospect of weaker growth at the pharmaceutical business and mentioned considerations that some expenditures on pharma research could be outsourced,” the group said in its statement.

Training Course

BioBasics: Biotech For The Non-Scientist

BioBasics: Biotech for the Non-Scientist is a two-day course for those who want to better understand the science driving the industry. The course starts with basic scientific concepts and quickly delves into the causes of genetic and infectious disease and the therapeutic strategies used to mitigate disease. The latest innovations in immunotherapies, gene therapy, checkpoint inhibitors, CAR-T and more are explained.

A Bayer spokesman told Reuters that the CEO’s remarks referred to previously announced plans to increase outside collaborations.

Late last month, Reuters reported that a management review at the pharma giant could lead to job cuts and outsourcing its drug-testing services. 

Last year, Bayer began a major reorganization that saw it merge its pharma R&D unit into one division that combined all its R&D activities for therapeutic areas including cardiology, gynecology, ophthalmology, hematology and oncology research. The company is anticipating revenue declines from some top drugs coming off patent in coming years and more competition for other drugs in its repertoire.

It’s been reported that as many as 1,000 jobs could be at stake as Bayer reviews its research sites.


Suggested Articles

Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.

Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.

Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.